Regeneron Pharmaceuticals, Inc. (LON:0R2M)
605.14
+5.74 (0.96%)
At close: Oct 3, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B USD in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.45
Revenue / Employee
$940.96K
Employees
15,106
Market Cap
46.16B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Regeneron Pharmaceuticals News
- 3 days ago - Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes - Nasdaq
- 4 days ago - Notable Wednesday Option Activity: CVS, HOOD, REGN - Nasdaq
- 4 days ago - Wednesday's ETF Movers: FBT, BIZD - Nasdaq
- 4 days ago - Regeneron (REGN) Sees Stock Surge as Core Product Sales Rise - GuruFocus
- 4 days ago - REGN Makes Bullish Cross Above Critical Moving Average - Nasdaq
- 5 days ago - Regeneron: Growth Catalysts Incoming - Seeking Alpha
- 5 days ago - Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 - GlobeNewsWire
- 5 days ago - Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin - CNBC